Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network-Reference-Cited by-同舟云学术

Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network

Published:2021-01 Issue: Volume:13 Page:1759720X2110371
ISSN:1759-720X
Container-title:Therapeutic Advances in Musculoskeletal Disease
language:en
Short-container-title:Therapeutic Advances in Musculoskeletal

Author:

Gaggiano Carla¹,Rigante Donato²,Hernández-Rodríguez José³,Vitale Antonio⁴,Tarsia Maria⁵,Soriano Alessandra⁶,Lopalco Giuseppe⁷,Iannone Florenzo⁷^ORCID,Abdel Jaber Masen⁸,Giacomelli Roberto⁹,Wiȩsik-Szewczyk Ewa¹⁰^ORCID,Cattalini Marco¹¹,Frassi Micol¹²,Piga Matteo¹³,Ragab Gaafar¹⁴,Sota Jurgen⁴,Zunica Fiammetta¹¹,Floris Alberto¹⁵,Sabato Vito¹⁶,Hegazy Mohamed Tharwat¹⁴^ORCID,Araújo Olga³,Pelegrín Laura¹⁷,Fabbiani Alessandra¹⁸,Renieri Alessandra¹⁹,Grosso Salvatore⁵,Fabiani Claudia²⁰,Frediani Bruno⁴,Cantarini Luca²¹^ORCID

Affiliation:

1. Research Center of Systemic Autoinflammatory Diseases and Behçet’s Disease, and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy; Clinical Pediatrics, Department of Molecular Medicine and Development, University of Siena, Siena, Italy

2. Department of Life Sciences and Global Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Rare Diseases and Periodic Fevers Research Centre, Università Cattolica del Sacro Cuore, Rome, Italy

3. Vasculitis Research Unit and Autoinflammatory Diseases Clinical Unit, Department of Autoimmune Diseases, Hospital Clinic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain

4. Research Center of Systemic Autoinflammatory Diseases and Behçet’s Disease, and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

5. Clinical Pediatrics, Department of Molecular Medicine and Development, University of Siena, Siena, Italy

6. Department of Internal Medicine, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy

7. Rheumatology Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy

8. Rheumatology Unit, Santa Chiara Hospital, Trento, Italy

9. Rheumatology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy

10. Department of Internal Medicine, Pulmonology, Allergy and Clinical Immunology, Central Clinical Hospital of the Ministry of National Defense, Military Institute of Medicine, Warsaw, Poland

11. Paediatric Clinic, University of Brescia and Spedali Civili di Brescia, Brescia, Italy

12. Rheumatology and Clinical Immunology, Spedali Civili, Brescia, Italy; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

13. Rheumatology Unit, Department of Medical Sciences, University and AOU of Cagliari, Cagliari, Italy

14. Rheumatology and Clinical Immunology Unit, Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt

15. Rheumatology Unit, AOU University Clinic, Cagliari, Italy

16. Faculty of Medicine and Health Sciences, Department of Immunology-Allergology-Rheumatology, University of Antwerp and Antwerp University Hospital, Antwerpen, Belgium

17. Clinical Institute of Ophthalmology, Hospital Clinic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain

18. Medical Genetics, University of Siena, Siena, Italy

19. Medical Genetics, University of Siena, Siena, Italy; Medical Genetics, Azienda Ospedaliera Universitaria Senese, Siena, Italy

20. Ophthalmology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy

21. Research Center of Systemic Autoinflammatory Diseases, Behçet’s Disease Clinic and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Policlinico ‘Le Scotte’, viale Bracci n. 1, 53100 Siena, Italy

Abstract

Background: This study aims at describing the therapeutic outcome of patients carrying the R92Q variant in the TNFRSF1A gene treated with anakinra (ANA) or canakinumab (CAN) and identifying any factors predictive of complete response to IL-1 inhibition. Methods: Clinical data of patients treated with ANA or CAN for recurrent inflammatory attacks due to the presence of the R92Q variant were retrospectively collected and analysed. Results: Data about 20 treatment courses with IL-1 inhibitors (16 with ANA and 4 with CAN) from 19 patients were collected. Mean age at disease onset was 20.2 ± 14.8 years. In 5 cases (26%) the R92Q variant was found in a family member affected by recurrent fever. The therapeutic response was complete in 13(68%) and partial in 2 patients (11%); treatment failure was observed in 4 cases (21%). Median AIDAI decreased from 10 (interquartile range [IQR] = 28) to 0 (IQR = 1) at the 12-month follow-up visit ( p < 0.001). Mean ESR and median CRP dropped respectively from 40.8 ± 24.8 to 9.1 ± 4.5 mm/h ( p < 0.001) and from 3.0 (IQR = 1.9) to 0.3 (IQR = 0.3) mg/dl ( p < 0.001) after 12 months of treatment. A steroid-sparing effect was observed from the third month of treatment ( p < 0.01). Thirteen patients (65%) were still on treatment at the last follow-up visit (median duration of treatment 17 (IQR = 38) months). The presence of R92Q mutation in a symptomatic relative ( p = 0.022), the relapsing remitting disease course ( p < 0.001) and the presence of migratory erythematous skin rashes during fever attacks ( p = 0.005) were associated with complete efficacy of IL-1 inhibitors. Conclusions: R92Q patients showed a favourable response to ANA and CAN, particularly when the mutation segregated in a family member and when a relapsing-remitting disease course or TNF-α receptor-associated periodic syndrome (TRAPS) typical skin rash were observed. In the subgroup of patients not taking advantage of IL-1 blockage different molecular mechanisms underlying the autoinflammatory picture are likely to exist.

Publisher

SAGE Publications

Subject

Orthopedics and Sports Medicine,Rheumatology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1759720X211037178

Reference53 articles.

1. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry

2. A systematic approach to autoinflammatory syndromes: a spelling booklet for the beginner

3. The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome

4. Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The past 25 years in paediatric rheumatology: insights from monogenic diseases;Nature Reviews Rheumatology;2024-08-07

2. The role of interleukin 1 in the development of human diseases: focus on Anakinra (IL-1 receptor antagonist);Rheumatology Science and Practice;2022-07-01